NITI Aayog CEO Amitabh Kant 
Business

India scaling up production of APIs: NITI Aayog CEO Amitabh Kant

India, a global hub for generic drugs, has launched a new scheme to boost production of active pharmaceutical ingredients (APIs) that are greatly dependent on the Chinese supply chain, according to NITI Aayog CEO Amitabh Kant.

migrator

New Delhi

Speaking at the 14th Annual BioPharma and Healthcare Summit, he said India is now gearing up for innovation in its pharmaceutical ecosystem focusing on speedy and scaled up delivery of new vaccines and personalised medicines.

He said India has launched a new scheme to boost production of active pharmaceutical ingredients that are greatly dependent on the Chinese supply chain. “We are planning to do complete manufacturing in India,” he said at the recently-held virtual summit organised by the USA-India Chamber of Commerce.

The summit was attended by major players from the US pharma sector, whose combined annual R&D budget is over $45 billion.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Delhi HC grants injunction in favour of Allu Arjun in personality rights case

Alliance mathematics, arithmetic will be shattered by generational shift in electorate: Vijay

Jana Nayagan leak row: Producer opposes anticipatory bail for freelance editor in MHC

Watch | SA Chandrasekhar's emotional video for Vijay goes viral ahead of TN Assembly polls

Venugopal gives privilege notice against PM to Lok Sabha Speaker over Saturday address to nation